- BriaCell Therapeutics Corp. (BCTX) has been awarded a **$2,054,651** non-dilutive research grant from the National Cancer Institute (NCI).  **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_0]** **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_1]** 
- The grant is designated to advance **Bria-PROS+**, BriaCell’s next-generation personalized off-the-shelf immunotherapy for prostate cancer.  **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_1]** 
- The funds will be used to complete manufacturing of Bria-PROS+ clinical supply and to support an upcoming Phase 1/2a trial in metastatic prostate cancer.  **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_0]** **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_1]** 
- Dr. William Oh, MD, Director of Precision Medicine, Yale Cancer Center, is the Principal Investigator for the upcoming clinical study.  **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_0]** **[1610820_69b9d0e4dfb54bfea7c63a0e0728aca6_1]**

BriaCell Therapeutics (BCTX)